IKR Publishers

IKR Journal of Clinical Medicine and Medical Research (IKRJCMMR)
Journal homepage: https://ikrpublishers.com/ikrjcmmr/
Volume-2, Issue-1 (January-February) 2026
OPEN ACCESS
ISSN: 3107-6521 (Online)

Digital Transformation in Clinical Pharmacy: A Kaleidoscope of Research, Practice, and Future Horizons

Saba Hameed Majeed[1*] **& Mohammed Murtadha**[2]
[1,2]Clinical Pharmacy Department, College of Pharmacy, AL-Nahrain University, Baghdad, Iraq

DOI:10.5281/zenodo.18241231

ARTICLE INFO

Article history:
Received : 03-01-2026
Accepted : 09-01-2026
Available online : 14-01-2026

Citation: Majeed, S. H., & Murtadha, M. (2026). Digital Transformation in Clinical Pharmacy: A Kaleidoscope of Research, Practice, and Future Horizons. *IKR Journal of Clinical Medicine and Medical Research (IKRJCMMR)*, 2(1), 1-12.

ABSTRACT **Review Article**

Digital revolution in clinical pharmacy is a fascinating combination of research, practical use, and future possibilities. Seen through a kaleidoscope, it reveals a world of possibilities, a spectrum of ideas that might very well redefine the field. Changes are mostly driven by issues of ongoing safety, adherence to rules, accessibility, fairness, and quality, with a focus on patient care and choosing the right medications. In healthcare, pharmacy is recognized as an allied health profession, yet it is also regarded a distinct career. Digital transformation is essentially about leveraging digital technology. The ultimate aim is to adapt to the evolving demands of both the business landscape and the market. Digital transformation arises from the combination of digital technologies and shifting client expectations.

Keywords: Digital Transformation, Clinical Pharmacy, Innovation in Practice, Future Horizons, Healthcare Technology, Research Integration.

**Corresponding author: Saba Hameed Majeed*
Clinical Pharmacy Department, College of Pharmacy, AL-Nahrain University, Baghdad, Iraq

1. Introduction

The Alchemy of Digital Change in Pharmacy

Digital transformation in clinical pharmacy represents a captivating alchemy of research, practice, and future horizons. Framed as a kaleidoscope, it reflects an imaginative spectrum that holds the potential to reshape the profession. Core drivers of change include considerations around continued safety, compliance, accessibility, equity, and quality. Recently, many health sectors undertook major digital change initiatives; clinical pharmacy is now at the tipping point of an accelerated digital transformation. (Mirzaian & Franson, 2021; Almeman, 2024)

Clinical pharmacy encompasses services and processes performed by pharmacists that prioritize clinical patient care and product selection. Within the context of health care, pharmacy is identified as an allied health profession; pharmacy is also considered a profession in its own right. Digital transformation refers to the process of using digital technologies to create new, or modify existing, business processes, culture, and customer experiences in order to meet changing business and market requirements. Digital transformation builds on the confluence of digital technologies and changing customer expectations. A research study articulating a framework for digital transformation in pharmacy describes six key components: (1) vision, (2) culture, (3) technology, (4) data, (5) processes, and (6) structure (Almeman, 2024; Van Veldhoven & Vanthienen, 2022; Zhang & Chen, 2024)

Successful transformations require an understanding of stakeholder ecosystems that influence adoption, governance, and collaboration. Key stakeholders that drive clinical pharmacy-related digital transformation include patients, pharmacists, regulators, healthcare providers, and pharmaceutical manufacturers. Recognizing the interdependencies among stakeholders can help address the challenges of competing priorities and misaligned incentives, allowing organizations to better tailor their technology investments. (Barata et al., 2022; David, 2025; Aungst, 2025)

Digital transformation is thus rooted in service delivery, and remaining focused on optimizing the process for delivering care ensures clinical pharmacy will stay knitted to its core purpose throughout the change journey. The following work narrates a kaleidoscopic account of what is known (research) and what is being done (practice) in clinical pharmacy digital transformation today, while illuminating several avenues for future change. (Almeman, 2024; Furtner et al., 2022; Ogundipe et al., 2025)

2. Foundations of Digital Transformation in Clinical Pharmacy

Digital transformation alters the how of providing care alongside the what. In this context, “clinical pharmacy” denotes the discipline responsible for the rational and evidence-based use of medicinal products at the individual patient level and defining the clinical pharmacy practice model. The field centres on the interaction between patients and healthcare professionals (prescribers and pharmacists) in decision-making about medications, and is vital for patient care and outcomes. But despite its importance in determining the desirable end points for digital transformation of pharmacy practice, the current influence of the transformation on the discipline remains poorly characterised (Almeman, 2024; Martini et al., 2024)

2.1. Definitions, Scope, and Frameworks

Digital transformation is often misperceived. Disparate changes can easily be construed as the onset of transformation yet fall short of actual transformation. Strikingly transverse, a strong speculative wave may then be perceived as the onset of a new metamorphosis. Yet, at a bewilderingly fast pace yet entirely two-dimensional, the kaleidoscope inner narrative still fully embodies the spirit underpinning that previous, even fleeting metamorphosis. Whether by means of low, unified speech-act density across the board, or through evidently imaginary illustrations devoid of direct ties to the eld, a continuum nonetheless extends from the misguided misperception of misperception to the authentic transformation of an audacious articulation. And yet, there seem yet two doubts for purely dissipative scorch trials not to leave scot free reflection and association, each directly questioning its rationale, Identity and Purpose. (Markus & Rowe 2023; Leso et al., 2024; Bocken et al., 2025; Thomas, 2024)

The field of clinical pharmacy encompasses the most gossamer strands of the kaleidoscope—sublaterally laced connections between patient, disease, and drug—that the evident signalling of a serious local upheaval just could have been misconstrued as the onset of a supposedly copious transition. Even if rescaling did not seem but a disappearance from view, certainly automation also comprised a basic technique of savings still valid even today. Likewise, upgraded definitions of clinical pharmacy or telehealth that withstood the earlier cleansing were never once brought back into play. Then again, unsettlingly diverse perspectives from patients and practitioners to regulators and supporters suggest a two-dimensional manifold well worth tracking. (Dreischulte et al., 2022; Marques et al., 2024; Huang et al., 2024)

Clinical pharmacy pertains to direct patient care and the use of medication to optimize health. As a mobility paradigm, it pivots around patient initials inside the bordered disease-drug matrix through nearest-neighbour curves. The second Strahler inventory unveils telemedicine throughout that matrix, including pharmacy, comprehensive estimators across all drugs, and specifications for antiretrovirals; details remain mosaic-lengthy at times, yet multifaceted irregularity did still prevail. Digital transformation embraces all content that crosses the full spectrum of functional provision; for the matrix and its tele-background, the sheer quantity of signalled disturbances indicates throughgoing change, irrespective of destination. Remaining topologically in the large then points to the core network of burdened, low-frequency Drug-Disease dimensions as already being the most transformed domain certainly a sizeable coincidence shift, albeit it has displaced (Ahmad et al., 2023; Liu et al., 2024; Khuntia et al., 2024)

The agog activity figure encompasses social network, mass media, telepharmacy, numeracy and acute replenishment, quoted transfer, CDSS, interactive service, data gathering, home-based and widespread services, InfoLab, vectored and II CC plus climate action. Another significant restructuring at local stage arises through between the paragraphs of cost containment and belief at set-zero. Another eclat lifts circuitry connectivity alone above even the overall project of filtering yet promptly makes the digital dimension disappear. Conclusively burnishing meteorite-themed sway, either format begs another thorough twilight purification, Precis and Tableau intertwining yet still protecting strategic intent. Reminiscence and foresight suggest continents whose flux regularities exhibit a saturation not dissimilar from that first calibration. (Armando, 2025; Abdelmonem et al., 2025; Karattuthodi et al., 2023)

Frameworks and models specifically Gøtzsche’s, Schmidt’s and Poma’s yet an overall sweep fails to mention any model save Paiz’s heavy model from collection, quasids here being setters and enablers still the most popular term escaping

mention—already draw attention at earlier purges. So does uncertainty, held right from the start yet reappearing through darkness and doubt and a retreat to mere signalling. Involvements and interdependences percolated right from warm-up trials at the rear still add relevant layersregulatory, economic or safety traffic reliably hindering large yet low-profile evolution through a leery, arm's-length commercialised investment still sufficing for up-saturation without extravagant layer-lending in the raisin stage. (Imam-Fulani et al., 2023; Raychaudhuri & Challa, 2025; Lai et al., 2024)

A kaleidoscope narrative stretches between the renovation theorem of Schröder's and the gradualism sported upon quasi-Calabi flow through singularity decay. Its alteration likewise lays itself open upon the regular unvary from initial through kinetic through polar. Initial musings on the marginal utility may do an overall detailed sweep bordering upon a fine. By contrast, combining ætherial elbow density functioning through much classical apparatus across steady-state expectation and flooding-state retribution allows quite liberally a sizeable drop-down opening of the narrative all the way back to the enlarged remembrance of Ellis. The eventual connection of bridges through absurd sesquilinear four into a mock universal invasion dashed an hour-plus exploration with damping dust by Feré nogging entirely the precrystallisation of wonder through pacing retina, emblazoned later on the blackboard, barely thereafter during rail-draining of the Parley ink. (Bridge, 2021; Francis, 2024)

2.2. Stakeholders and Ecosystems

Pharmaceutical care's evolution points to reimagined clinical service promotion that enhances service availability, stakeholder engagement, and access to care outside conventional settings (Almeman, 2024). Digital technologies facilitate wider adoption of pharmacy services and expanded roles, supported by health churn, population-wide conditions, and shrinking appointments. (Martini et al., 2024; Adekola & Dada, 2024; Aungst, 2025)

Increasing diversity of stakeholders, partnerships, and participation models brings greater complexity and wider-ranging implications as interdependencies permeate the wider health system. Fulfilment of digital pharmacy promises relies on societal, economic, political, and ideological factors; technical scaffolding merely provides the means. Diagrammes can trill in the clinical domain for therapeutic relevance and safety-risk balance, but to go viral people, institutions, societies, nations, and systems must coordinate to enliven the enthralling possibilities. (Bradley & Mahmoud, 2024; Sajwani et al., 2024; Brandão & Santos, 2025)

3. Current Landscape: Mapping the Innovations

Digital transformation in clinical pharmacy is gathering momentum, reshaping the profession at an unprecedented rate. The marriage of digital technology and clinical pharmacy promotes innovation across research, practice, curriculum development, and related spheres. (Almeman, 2024; Martini et al., 2024)

Digital transformation denotes a fundamental change brought about by the increasing adoption of digital technology. Clinical pharmacy comprises patient-centered pharmacy practice, pharmaceutical care, clinical pharmacy services, and other closely allied areas. Digital transformation reimagines the life science industry and holds the promise of revolutionizing the patient and healthcare experience (Almeman, 2024). The inception of electronic health records triggered widespread change in healthcare organizations. Today, the pace of innovation quickens with artificial intelligence, telepharmacy, pharmacy automation, digital therapeutics, and digital pharmacovigilance, whose adoption touches all aspects of pharmacy practice and education. (Sharma et al., 2025; Subha et al., 2024; Singh & Kaunert, 2025)

The recent COVID-19 pandemic reverberated through the profession, increasing the utilization of established digital-health technologies while prompting fresh thinking about how to include the digital space during the transformation itself. The need to engage the profession in an imaginative and comprehensive manner drove the development of a descriptive and analytical approach termed the "kaleidoscope" to capture the life-science ecosystem as it rapidly evolves and the key questions that need to be addressed within it. A kaleidoscope provides a changing view depending on the observer's perspective, making it a fitting analogy. Subcultures within the ecosystem interpret the changes differently and pursue distinct objectives. (Tuitert et al., 2024; Hannemann et al., 2021; Qiu et al., 2024)

Six foundational elements ground clinical pharmacy and drive the call for transformation: the role of pharmacy practice and understanding of practice models, the life-science ecosystem comprising organizations and networks beyond pharmacy, the broad definition of digital technology that encompasses more than is commonly considered, the evolving spectrum of research and its interrelation with practice, the importance of the patient voice and prioritization of the patient experience, and the growing ubiquity of information systems and communication technology. (Thornewill et al., 2022; Hartis, 2024; Almeman, 2024)

3.1. Electronic Health Records and Interoperability

Digital transformation in pharmacy is guided by influential models and frameworks that serve as lenses through which to examine transformation holistically. Four foundational models emerged from a survey of the literature: Dynamic Capabilities, the Technology-Organization-Environment Framework, the Digital Transformation Framework, and the Digital Health Transformation/Six-Path Framework. These

models structure components that dynamically influence the pace and direction of transformation by guiding conducive practices, choices, and decisions. Four categories of stakeholders shape the larger environment for transformation across health systems and sectors: (1) Regulatory Bodies, including health and pharmacy regulation authorities that govern operations, ensure safety, and define the scope of practice; (2) Organizations that direct internal incentives, financing, and prioritization; (3) Bespoke Experiences, encompassing patient-centric approaches to care, engagement, satisfaction, and journey; and (4) Device, Logistics, and Supply-Chain Managers, who focus on medicines inventory, technology, equipment, and devices fundamental to practice (Almeman, 2024; Awais et al., 2025; Sun et al., 2025; Khan et al., 2025)

3.2. Artificial Intelligence and Decision Support

The progressive adoption of artificial intelligence (AI) in the clinical setting, through the development and integration of algorithms and associated technologies, is changing the way health professionals gather, analyze, and interpret data to inform clinical decisions and make judicious judgments in managing risks. AI-powered clinical decision support (CDS) systems, which provide recommendations based on the processing and consideration of multiple variables drawn from voluminous datasets, such as those typically housed in electronic health records, are thus evolving into key decision-making tools in clinical practice. By helping health professionals cut through the noise associated with large volumes of data, AI is allowing them to devote more attention to higher-level synthesizing and integrating of knowledge and information (Elhaddad & Hamam, 2024).

3.3. Telepharmacy and Remote Patient Care

Access to medication therapy management, immunization services, and chronic disease state monitoring is facilitated through telepharmacy, remote patient care, and drug adherence programs. These services ensure patients remain engaged and involved in their treatment and support the continuity of care and refills after discharge or transfer. Telepharmacy also helps maintain therapeutic standards and pharmaceutical care provision at authorized places and in remote, underserved, or disaster-stricken areas. Global telepharmacy platforms establish remote and decentralized operational capacity to provide comprehensive and reliable pharmaceutical care regardless of geographic boundaries. Advancements in information-and-communication technology stimulate diverse telepharmacy concepts that leverage electronic information transmission to obviate temporal, spatial, and supply-chain barriers, enable omnipresent pharmaceutical services, and widen access to therapeutic knowledge. Telepharmacy services empower patients to acquire and understand medication therapy irrespective of their geographic location, ensuring healthcare engagement and responsibility regardless of health system development. (Banji et al., 2024; Awala & Olutimehin, 2024)

3.4. Pharmacy Automation and Robotics

Pharmacy practice worldwide is evolving rapidly, driven by advances in automation and robotic technologies, which promise higher throughput, enhanced accuracy, and relief from tedious tasks. By integrating these innovations, pharmacies can redirect clinical staff toward more patient-centered activities, such as medication management, education, and expanded clinical services that improve patient outcomes (Almeman, 2024). The number of dispensing errors remains high, despite automation and control measures, underscoring the critical need to deploy pharmacy robots (Alahmari et al., 2022). In the United States alone, over 30 million errors occur annually, with incorrect dispensing, dosing, and intravenous drug preparation ranking among the most common. Robotic-assisted pharmacy systems are improving the safety and efficiency of dispensing, mitigating the detrimental effects of overwork and time pressure faced by pharmacy personnel. (Um et al., 2024; El Hajj et al., 2025)

3.5. Digital Therapeutics and Patient Engagement

Digital therapeutics (DTx) deliver evidence-based software interventions to prevent, manage, or treat a medical disorder or disease (Phan et al., 2023). By enhancing patient engagement and education, DTx can improve health outcomes, support behavior change, and help patients navigate complex treatment regimens (Almeman, 2024). These software programs offer a new treatment modality to supplement pathology or symptom-focused therapies, especially when care paradigms shift from the treatment of isolated symptoms toward the management of broader syndromes. Patients diagnosed with post-traumatic stress disorder, for example, may benefit from DTx addressing associated anxiety and insomnia.

As DTx become clinically validated across various indications, pharmacy professionals have the opportunity to maximize their potential within the context of each treatment. Such engagement requires a foundational understanding of current DTx offerings and pathways supporting their translation into practice. Digital techniques can augment existing pharmacy practices, shaping an integrated and holistic digital-experience offering, and contribute to DTx directly, ensuring that patients can derive maximum benefit. Pharmacists are also positioned to assume a leading role in DTx development ventures and partnerships, provided they adopt an entrepreneurial approach to the exploration of digitally disruptive opportunities. (Shafai & Aungst, 2023; Hussian et al., 2025; Lumbreras et al., 2024)

3.6. Pharmacovigilance in the Digital Age

Adverse drug reactions are the primary reasons for the withdrawal of medicinal products. To better convey the safety concerns related to a medication once it has been placed on the market, the concept of benefit–risk monitoring becomes

essential. Benefit–risk monitoring ensures the continued evaluation of products while in the market and involves two components: signal detection and signal reporting. The availability of large quantities of heterogeneous data regarding the safety of health products opens new perspectives for the functioning of the post-marketing safety monitoring system. The introduction of electronic health records made it possible to automatically signal data, allowing for a better, clearer, and easier understanding of adverse events. The notion of spontaneous reporting of an adverse event by a health professional remains still relevant, especially for products for which the volume of data remains limited. Beyond a simple communication to signal the occurrence of a possible safety problem, the speed of reporting becomes an essential component across the whole "classical" pharmacovigilance system. The involvement of the patients and their participation to signal an adverse event is a growing trend that is likely to enhance the speed and the transmission of information. The future of pharmacovigilance will be a mixture of more scientific, less communication-based, and patient-centered safety and precaution. Pharmacovigilance 4.0 deals with the vast quantities, heterogeneous types, and distributed nature of data describing the safety of drugs, and it encompasses the full range of situations involving the collection, alarm generation, modelling, and/or treatment of a signal in the post-marketing environment of health products. Adapted pharmacovigilance remains crucial for the whole societal and governmental system of drug safety. (Zazzara et al., 2021; Amangelsin et al., 2023; Shyam et al., 2023; Mahmood et al., 2022)

4. Clinical Impact: Evidence, Outcomes, and Patient Experience

The instant danger of irrelevance hung over health systems as they grappled with the chaos of the pandemic yet new digital endeavors poured forth from care organizations worldwide. Evidence swelled that digital solutions nurtured connections with patients, expanded access in vulnerable communities, and refined virtual teamwork across silos. These rays of hope while tenuous coalesced under the flag of a distinct concept: digital maturity. The shift from "going digital" to acknowledging transformation's multifaceted nature echoed across sectors. (KOMI et al., 2021; Blasioli & Hassini, 2022; Batool & Lopez, 2023)

The very fabric of maturation wove the stories together, recognizing that enhancements in one dimension inevitably music new interrogations and foundations in others. Curators began to contemplate and lift their sights toward new dimensions that now swirl faster than ever through multiple health systems (Almeman, 2024).

Acknowledging these transitions and complexities shaped the ensuing reflections on clinical pharmacy, the profession most proximate to medication therapy management. Rather than fixating merely on technological adoption, it became evident that digital transformation encompassed far broader mindsets and aspirations integral to success. Clarity on these thematic opportunities deepened comprehension of associated innovations and momentum shaping the trajectory for pharmacy and health. (Schiuma et al., 2022; Padua, 2021; Ahmad et al., 2022)

Connected approaches, frameworks, and lenses became the ultimate companions on this survey. Four main facets attached directly to digital pharmacy: evidence concerning medication therapy safety and adherence; optimization of personalized approaches to pharmacotherapy; consequential shifts in teams, systems, and workflows; and enhancements to efficiency while elevating patient and staff experiences. Every illumination gained strength through its distinct vantage yet formed only a single hue of adventure that remains inextricably intertwined with myriad systems, partners, and activities. (Ibrahim & Xue, 2024; Ezeudoka & Fan, 2024; Fan & Ukaegbu, 2024)

4.1. Medication Safety and Adherence in a Connected World

The melange of medication safety and adherence forms an alarming conundrum in contemporary healthcare. Essential for effective disease management, medication ranks second among contributors to hospitalisation after human neglect. Yet, US estimates found a staggering 76.6 million drug-related morbidity and mortality events annually, resulting in about 2 million hospital visits (Bates et al., 2022). Of all prescribed drugs, a staggering 44 to 78% are deemed unnecessary or inappropriate for the older population alone, with an associated $421 billion economic burden. Poor adherence threatens individual health and safety, while prescriptive and administration hurdles affect broader societal equity (Arbuckle et al., 2019). Non-adherence peaks at 50% in chronic illnesses, provoking disease progression, health expenditure, and early mortality (Almeman, 2024). Digital medication regimens may mitigate these profound challenges.

4.2. Personalized Pharmacotherapy through Data

With information overload, decision fatigue, and constant distractions, accessing relevant knowledge becomes increasingly arduous. Contemporary healthcare institutions muster vast volumes of mailing lists, recommendations, ratings, protocols, pathways, standards, templates, tools, algorithms, apps, sources, signals, and evidence to aid qualified choices. Only through timely guidance can continuously evolving information and data be effectively filtered to safeguard patients. The start of the Fourth Industrial Revolution intensified these concerns. Proliferating challenges demand parallel sharpening of strategies and tools to meet new, sophisticated expectations for protecting society's most precious asset: health. (Sripathi & Leelavati, 2024; Aslam et al., 2024; Ziatdinov et al., 2024)

Pharmacogenomics merges pharmacology and genomics to help individualise drug therapy with the aim of optimizing efficacy and minimising adverse effects. Biomarkers (any measurable variable that reflects a normal or pathological biological process) are essential: 1) for identification of predisposition, 2) for prediction of machineries about consequence, and 3) for relative assessment of tolerability in various systems. In addition to genomics, pharmacogenetics relies on polygenics and metabolomes to identify patient-specific biomarker drug-response relationships. Sophisticated AI-embedded generation techniques are required for adaption within pluralistic healthcare structures, interim generation systems collaborating with open-sourced or emergent-generation designs, and modelling off-cache evidences or essentials. (Pirmohamed, 2023; Taherdoost & Ghofrani, 2024; Qahwaji et al.2024; Molla & Bitew, 2024)

Game-changes in empowering medicos to concentrate on most pertinent cases, federated and collective fructification of massive, recent data-sets populating local topology learning automata to form common basis and potentiating downstream procedures, robotics-assisted on-boarding of acquirables (ordinary multi-modal content, cross-channel extraction, etc.) to nurture introductory seeds, and other trends recently arrived or anticipated in, yet empowering educators to devote luxury time differentiating most timely yet pertinent evolutions across multi-faceted topology (Fractal, Haeckel, etc.) within and beyond the disciplines (Almeman, 2024).

4.3. Workflow Efficiency and Team Collaboration

Emergence of digital tools is expected to influence the productivity of pharmacy professionals and the performance of pharmacy teams. Tools have the potential to positively impact completion of core tasks, thereby improving team performance. However, they must be better understood and adapt a step further to augment teams and transform the productivity of pharmacy work (Baines et al., 2018).

Clinical pharmacy teams are expected to engage in review processes (e.g., in either verifying general laboratory parameters for a prescriber or a medication review for a patient), broadly considered a core task. Reviews typically involve a common information-flow trajectory: gathering existing data, checking for expected behaviour compared to the existing therapeutic information, identifying factors that deviate from expected behaviour relative to existing therapy, and documenting the findings. Digital tools that facilitate one or more of these information-flow substeps can therefore enhance the pharmacy team's potential completion of a core task, impacting overall team performance. Such digital tools have also been proposed to extend to numerous types of audit and verification processes (Almeman, 2024).

5. Challenges and Barriers: Navigating Noise and Risk

Navigating the wave of digitalization creates noise that complicates clinical pharmacy and amplifies the risk of static. Data privacy, security, and regulatory compliance concern organizations across the healthcare landscape; adherence and acceptance court users in pharmacy practice; equity, access, and the digital divide jeopardize care for vulnerable populations; and economic considerations of value and sustainability limit growth in size and scope. To surf the tidal wave from one innovation to the next requires grounded awareness of the barriers steeling practice. (Almeman, 2024)

5.1. Data Privacy, Security, and Compliance

Digitalization fuels the transition from a product- to a patient-centered approach and transforms the responsibilities of all healthcare professions, including pharmacy. Digital technologies extend the pharmacy scope and modify the *Four Pillars of Pharmacy Practice* accordingly: 1. population health, via advanced analytics; 2. personalized pharmacotherapy, with patient data, genomics, and bioinformatics; 3. medication adherence and safety, connected to patients and monitored by products such as *MedEye; and 4. end-to-end care, realizing prescriptions by *MedRobo* and allowing remote pharmacist supervision (Almeman, 2024). Digitalization both builds on and enriches community pharmacy practice, accentuating its crucial role as the most accessible healthcare profession and as an indispensable partner in national health systems (Laetitia Hattingh et al., 2015).

5.2. Usability, Acceptance, and Training

The evolution of automation and digitalization is the most transformative development since the advent of the internet. The widely acknowledged success factors of any digital system adoption include usability, acceptance, and training. A user-centered design approach that promotes meaningful involvement of end users in the development process provides the basis for the first two success factors. Implementation planning and sound change management during system deployment are usually beneficial in promoting user acceptance of innovations introduced into established practices, including predictive algorithms being introduced into the clinical medication management process (Herrmann et al., 2024). Available literature on digital transformation in pharmacy and health care emphasizes that high-quality training during implementation is essential to the adoption process and that the pharmacy team is an important stakeholder in these processes (MacLure & Stewart, 2015). The pharmacy team's involvement in selection and design decisions can therefore be seen as a means of enriching the cycle.

5.3. Equity, Access, and Digital Divide

Digital transformation has altered patient interactions with healthcare. Social media, e-commerce, artificial intelligence (AI), telepharmacy, and digital therapeutics are reshaping practices. The tempo of change is increasing. Digital transformation creates a promising yet complex landscape, entailing expanded roles for clinicians and coordinators in evolving practice models. Overarching frameworks can guide progress, while new opportunities to improve service availability, safety, and outcomes emerge. Institutional harmonization, governance, interoperability, and collaboration are essential for transformation.

Pharmacy digital transformation encompasses the interplay of technology and communication that enriches service delivery and patient experience (Almeman, 2024). The primary focus is the pharmacy practice domain within healthcare systemsdrug therapy at the population and individual levels. Pharmacy services that enhance drug usage, benefit monitoring, and therapy modification underpin the transformative pharmacy ecosystem.

5.4. Economic Considerations and Sustainability

The kaleidoscope pivots to economic considerations underpinning the digital transformation of clinical pharmacy. The shift toward data-centric structures has altered pharmaceutical enterprises' approaches to financial planning, requiring sophisticated analyses of risk versus return on investment (Almeman, 2024). This paradigm change introduces short-term value measures that account for the ongoing transition toward fully realizing long-term investment and revenue objectives. The traditional capital rules governing clinical pharmacy investment remain applicable but, together with conventional valuation practices, must be augmented by the new analytical approaches.

Financial limitations and uneven economic distributions affect the ability of some nations to embrace digital transformations. Such differences stem from lack of access to certain drugs and vaccines, reluctance to join the digitized movement due to flaws in existing models, and disparities in financing arrangements among wealthier countries. While industrialized countries initiate digital revolutions and design transformational blueprints that developing nations subsequently adopt, the uncoordinated programs pursued by individual countries often preclude collection of worldwide databases consistent enough to guide future transformations. Nevertheless, digital transformation initiatives are taking root even in low-income nations, including the proposal of a Digital Transformation Strategy to help broaden PK-12 education system access.

6. Future Directions: Trends Steering Tomorrow's Clinical Pharmacy

Digital transformation expands opportunities for achieving ambition in health, evolving from the core vision of enhanced quality to new explorations of enhanced experience and outcomes. As transformation accelerates, development transitions from the familiar to the novel and uncharted, from continual adjustment within prevailing frameworks to larger transformations of the tools, frameworks, practices, and modalities underpinning health interventions (Almeman, 2024).

Real-world evidence and active-learning health systems are becoming preeminent strategic themes for healthcare. Together, they encourage a continuous cycle of relevant research, reflection, discovery, and adjustment that enhances resilience and adaptability in the face of dynamic local health challenges. Advanced data analytics, particularly through generative digital technologies, promise vast new capabilities for deep insight and foresight into health status, treatment quality, readiness for care design, options selection, experience enhancement, outcome prediction, and improvement opportunities. Embedded-care models and population-health initiatives stimulate efforts to redesign solutions for integration into broader or pre-existing interventions at community scale, enhancing both coverage and mission. Policy harmonization, standardized oversight, and global systemic insight-sharing are priorities for accelerating and broadening transformation while mitigating chaos, duplication, and divergence.

6.1. Real-World Evidence and Learning Health Systems

Learning health systems (LHS) combine diverse perspectives, stakeholders, and technologies to generate real-world evidence (RWE) collaboratively and iteratively. Knowledge gleaned from two primary activities—clinical care and health-related research—informs life sciences guidance, clinical practice, and public policies. LHS encompass actions in clinical practice, observational studies, and health-related R & D. Sensor systems and artificial intelligence create knowledge from patient experience, generate healthcare innovations, develop RWE, and analyze managerial and technical issues. The digital transformation of clinical pharmacy inspires the transformation of LHS toward RWE with continuous improvement of services to an increasing percentage of patients and devices (Almeman, 2024). Extended clinical pharmacy activities—monitoring, safeguarding, and evaluation of health outcomes—stem from pharmacovigilance, supporting the continuous evolution of clinical pharmacy (Del Rio-Bermudez et al., 2020).

6.2. Advanced Analytics, Generative Technologies, and Beyond

Digital transformation in clinical pharmacy today converges towards a kaleidoscopic vision characterized by advanced analytics, generative technologies, and large language models (LLMs). Statistical analysis of large datasets has long been central to health research and practice for developing insights on healthcare and patient populations. Today, advanced

analytics—from machine learning to deep learning—fosters the integration and utilization of heterogeneous, complex, longitudinal data to forge transformations in health and health delivery on a vastly greater scale. Generative technologies—generative adversarial networks (GANs) among them—expand the frontier of what can be conceived by allowing algorithms to create data and information, from drug design to complex documents. LLMs allow for the analysis, summarization, and effective dialogue surrounding vast amounts of text, including the scientific literature, clinical handover reports, patient notes, and alerts. These transformative capabilities, partnered with recent advances in mobile, sensor, composite drug design, and monitoring technologies, augur the rise of significantly augmented health delivery. Such enhancements encompass understanding of a patient's condition and the paths forward to optimal health, the continuously personalized adaptation of interventions—therapeutic, preventive, and supportive—to the individual along those paths, the generation of integrated documents that convey the status and needs at a glance, the preparation of entire publications in specified styles, the transposition of information into multiple languages, and far more (Almeman, 2024).

6.3. Embedded Care Models and Population Health

Under the ubiquitous pressure of patient-centeredness and community care, services in highly industrialized societies are evolving toward integrated approaches, consonant with broader goals of population health. At the clinical level, the aim is to expand capacity, maximize efficiency, and establish seamless interconnectedness among various in situ facilities. At another level, attention is turning to health stressors arising upstream in the health-delivery system and from socio-economic and geographic disparities among communities. As urgent upstream issues combine with the chronic and multi-morbidity burdens generally associated with aging, the need for integrated care expands at an increasing pace. Clinical pharmacy already plays a crucial role in many types of integrated care, and the potential to evolve remains vast (Harrington & Burge, 2018).

Communities exhibit wide variation in population health and pharmacotherapy profiles. Upstream issues, such as socio-economic disparity among communities served, are now joining chronic and multi-morbidity burdens associated with aging. Integration, a priority for the architecture of health-care systems, facilitates collaboration among multiple health-service providers to address co-morbidity, while estimating the clinically effective capacity needed by health systems to handle the entire connected population remains a significant challenge. Embedded-care models providing remote consultation services based on digital communication technologies (DCTs) offer new possibilities for building expansive integrated-care ecosystems that span multiple entities (Almeman, 2024). Integration and connectedness across all locations thus create the motivation to explore embedded-care approaches in connection with digital transformation. (Sanderson et al., 2023; Winter et al., 2023; Jaušovec & Gabrovec, 2023; Ma, 2024; Batool, 2025)

6.4. Policy, Standards, and Global Collaboration

Digital operators, content creators, and data managers constantly arrive and depart—filling specific needs, proposing options, and shaping opportunities at different rates; yet many have already decoupled, cascading a stream of emergent trends. Recent practices such as data-driven strategy formulation, consolidated care pathways spanning boundaries between scientific, professional, and regulatory knowledge domains, and increasingly comprehensive consideration of patient predispositions and situations during therapy design, all offer flux while simultaneously appearing increasingly mature (Almeman, 2024). The same applies to national and regional collaborative efforts that match proposals against local challenges and priorities, form cross-agency, cross-institutional, or ad-hoc groups; or simply review and publish, closely coupling what fragments are available for locally pertinent implementations. An increasing number of standards echo global solidarity in dealing with the COVID-19 pandemic. (Esu & Dessì, 2024; Gostin, 2023; Aginam 2024; Muqsith)

Governance has shifted from extensive unified global efforts to the establishment of internationally connected but locally anchored frameworks, articulating high-level principles and broader intentions alongside pathways tailored to address a plethora of diverse situations and aspirations. Thus, collaborative frameworks accommodate local agendas at consortium, regulatory, or shared-use level coordination, supporting entities that independently self-inform across challenges while remaining interlinked (Novovic, 2022; Maskrey et al., 2023; Zhang et al., 2024)

7. Conclusion

Digital transformation in clinical pharmacy is an evolving spectre of creativity, identifying unmet clinical needs and unrealised solutions. While change is gradual, its tempo is rising as capabilities ramp up, regulatory principles converge, and COVID-19 reshapes healthcare priorities. Clinical pharmacy, pharmacy practice, and pharmacy services are often used interchangeably; here, clinical pharmacy denotes care activities targeted on patients rather than drugs. Frameworks from various domains illuminate the kaleidoscope, depicting your practice as a dynamic interplay among diverse, evolving components. A multifaceted landscape of stakeholders, ecosystems, and channels defines the currents of adoption and diffusion that shape the journey. The journey begins by framing digital transformation in clinical pharmacy, outlining key concepts and principles that focus exploration of current innovations and emerging trends. (Thornewill et al., 2022; Almeman, 2024; Adekola & Dada 2024; Martini et al., 2024)

Digital transformation in clinical pharmacy embraces innovations creative approaches that address unmet clinical needs through novel technology or new uses of existing technology. A kaleidoscopic lens captures the imaginative potential and multifaceted dimensions of change while helping stay grounded in key concepts and frameworks. Drawing on works from over fifty individuals and organisations, the landscape encompasses numerous innovations and motivates exploration of the deployment spectrum. Awareness of promising solutions motivates experimentation, generates valuable learning, and accelerates progress. The spectrum depicts use alone; widespread adoption requires scaling beyond initial uptake, extending to additional stakeholders and components. Adapting twenty- and counting capabilities from pharmacy development, the framework helps structure objectives, leverage proven approaches, and identify priority areas. (Almeman, 2024)

8. References

1. Mirzaian, E., & Franson, K. L. (2021). Leading a digital transformation in pharmacy education with a pandemic as the accelerant. *Pharmacy*. https://www.mdpi.com
2. Almeman, A. (n.d.). The digital transformation in pharmacy: Embracing online platforms and the cosmeceutical paradigm shift. *Journal of Health*. https://www.springer.com
3. Van Veldhoven, Z., & Vanthienen, J. (2022). Digital transformation as an interaction-driven perspective between business, society, and technology. *Electronic Markets*. https://www.springer.com
4. Zhang, J., & Chen, Z. (2024). Exploring human resource management digital transformation in the digital age. *Journal of the Knowledge Economy*. https://www.ncbi.nlm.nih.gov
5. Barata, J., Maia, F., & Mascarenhas, A. (2022). Digital transformation of the mobile connected pharmacy: A first step toward community pharmacy 5.0. *Informatics for Health and Social Care*, *47*(4), 347–360. https://www.uc.pt
6. David, C. O. (2025). *An index of research projects at the Department of Pharmacy*. University of Malta. https://www.um.edu.mt
7. Aungst, T. D. (2025). Beyond the fill: Navigating pharmacy's technological future in 2050. *Journal of the American Pharmacists Association*. https://www.japha.org
8. Furtner, D., Shinde, S. P., Singh, M., Wong, C. H., & Setia, S. (2022). Digital transformation in medical affairs sparked by the pandemic: Insights and learnings from COVID-19 era and beyond. *Pharmaceutical Medicine, 36*(1), 1–10. https://www.springer.com
9. Ogundipe, A., Sim, T. F., & Emmerton, L. (2025). Prescription for digital evolution: Transformative recommendations for pharmacy practice in the digital age. *Journal of Pharmacy Practice, 38*(2), 237–248. https://journals.sagepub.com
10. Martini, N., Sajtos, L., Idio, L., Kaur, M., Sweeney, N., Zhang, C., & Scahill, S. (2024). The future of pharmacy work: How pharmacists are adapting to and preparing for technology infusion. *Exploratory Research in Clinical and Social Pharmacy, 15*, 100472. https://www.sciencedirect.com
11. Markus, M. L., & Rowe, F. (2023). The digital transformation conundrum: Labels, definitions, phenomena, and theories. *Journal of the Association for Information Systems, 24*(2), 328–335.
12. Leso, B. H., Cortimiglia, M. N., Ghezzi, A., & Minatogawa, V. (2024). Exploring digital transformation capability via a blended perspective of dynamic capabilities and digital maturity: A pattern-matching approach. *Review of Managerial Science, 18*(4), 1149–1187.
13. Bocken, N., Pinkse, J., Ritala, P., &Darnall, N. (2025). Moving beyond circular utopia and paralysis: Accelerating business transformations towards the circular economy. *Organization & Environment*. https://journals.sagepub.com
14. Thomas, A. (2024). Digitally transforming the organization through knowledge management: A socio-technical system (STS) perspective. *European Journal of Innovation Management*. https://www.emerald.com
15. Dreischulte, T., van den Bemt, B., &Steurbaut, S. (2022). European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: A position paper. *International Journal of Clinical Pharmacy, 44*(4), 837–842. https://www.springer.com
16. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics, 16*(3), 332. https://www.mdpi.com
17. Huang, X., Estau, D., Liu, X., Yu, Y., Qin, J., & Li, Z. (2024). Evaluating the performance of ChatGPT in clinical pharmacy: A comparative study of ChatGPT and clinical pharmacists. *British Journal of Clinical Pharmacology, 90*(1), 232–238. https://onlinelibrary.wiley.com
18. Ahmad, T., Boit, J., &Aakula, A. (2023). The role of cross-functional collaboration in digital transformation. *Journal of Computational Intelligence and Robotics, 3*(1), 205–242.
19. Liu, Y., Zhang, Y., Xie, X., & Mei, S. (2024). Affording digital transformation: The role of industrial Internet platform in traditional manufacturing enterprises digital transformation. *Heliyon*. https://www.cell.com

20. Khuntia, J., Saldanha, T., Kathuria, A., & Tanniru, M. R. (2024). Digital service flexibility: A conceptual framework and roadmap for digital business transformation. *European Journal of Information Systems, 33*(1), 61–79.
21. Armando, L. G. (2025). Analysis of real-world data and update of a clinical decision support system (CDSS) to investigate and support quality and sustainability of pharmacological … *Depositolegal.it*.
22. Abdelmonem, R., Lasheen, P., Hanafi, A., & Magdy, A. (2025). A comprehensive review of improvements in clinical pharmacy: Integration of AI, pharmacovigilance, telepharmacy, legalization, and multidisciplinary collaboration for enhanced healthcare delivery. *Journal of Pharmaceutical Sciences and Drug Manufacturing – Misr University for Science and Technology*, *2*(1), 89–99.
23. Karattuthodi, M. S., Krishnan, G., Aiswarya, A. V., Sarath Chandran, C., Nair, S. S., Thorakkatil, S. A., & Arain, S. (2023). A systematic review on pharmacist-led pharmaceutical care optimization through virtual platforms. *Journal of Pharmaceutical Health Services Research, 14*(1), 2–13.
24. Imam-Fulani, Y. O., Faruk, N., Sowande, O. A., Abdulkarim, A., Alozie, E., Usman, A. D., Adewole, K. S., Oloyede, A. A., Chiroma, H., Garba, S., &Imoize, A. L. (2023). 5G frequency standardization, technologies, channel models, and network deployment: Advances, challenges, and future directions. *Sustainability*, *15*(6), 5173. https://www.mdpi.com
25. Raychaudhuri, S., & Challa, T. (2025). Challenges in the design & development of efficient (high power) lighting systems. *Optik*.
26. Lai, Y., Li, Y., Liu, Y., Chen, P., Zhao, L., Li, J., & Xie, Y. M. (2024). Application of bi-directional evolutionary structural optimization to the design of an innovative pedestrian bridge. *AI in Civil Engineering*. https://www.springer.com
27. Bridge, T. D. T. (2021). *Bridged disconnection of bridges: A poetic and philosophical account*.
28. Francis, G. (2024). *The bridge between worlds: A brief history of connection*.
29. Adekola, A. D., & Dada, S. A. (2024). Entrepreneurial innovations in digital health: Strategies for pharmacists to expand clinical services. *International Journal of Engineering Research and Development, 20*(11), 1094–1101.
30. Bradley, S., & Mahmoud, I. H. (2024). Strategies for co-creation and co-governance in urban contexts: Building trust in local communities with limited social structures. *Urban Science*. https://www.mdpi.com
31. Sajwani, B., Al-Shboul, M., & Maghyereh, A. (2024). Do board characteristics affect financial sustainability? The COVID-19 pandemic experience. *Journal of Financial Reporting and Accounting*.
32. Brandão, A. S., & Santos, J. (2025). A multi-dimensional framework for assessing the societal benefits of collaborative R&I projects over time. *IPB Journal*.
33. Sharma, S., Subbarao, N., Jha, S. K., & McKenna, S. (2025). Revolutionizing healthcare: Transforming healthcare—Modes, technologies, and implementation. *Healthcare Studies*.
34. Subha, S., Shanmugathai, M., Prasanth, A., Varagi, S. S., & Dhanashree, V. (2024). Digital transformation in the pharmaceutical and biotech industry: Challenges and research directions. In *Digital Twins in Industrial Production and Smart Manufacturing*.
35. Singh, B., & Kaunert, C. (2025). Accelerating healthcare outcomes uplifting patient experiences pairing artificial intelligence (AI): Transforming the healthcare industry in the digital arena. *Impact of Digital Solutions for Improved Healthcare Delivery*.
36. Tuitert, I., Marinus, J. D., Dalenberg, J. R., & van't Veer, J. T. (2024). Digital health technology use across socioeconomic groups prior to and during the COVID-19 pandemic: A panel study. *JMIR Public Health and Surveillance*, *10*(1), e55384.
37. Hannemann, N., Götz, N. A., Schmidt, L., Hübner, U., & Babitsch, B. (2021). Patient connectivity with healthcare professionals and health insurer using digital health technologies during the COVID-19 pandemic: A German cross-sectional study. *BMC Medical Informatics and Decision Making, 21*(1), 250. https://www.springer.com
38. Qiu, Y., Huang, H., Gai, J., & De Leo, G. (2024). The effects of the COVID-19 pandemic on age-based disparities in digital health technology use: Secondary analysis of the 2017–2022 Health Information … *Journal of Medical Internet Research*. https://www.jmir.org
39. Thornewill, J., Antimisiaris, D., Ezekekwu, E., &Esterhay, R. (2022). Transformational strategies for optimizing use of medications and related therapies through US pharmacists and pharmacies: Findings from a national study. *Journal of the American Pharmacists Association*, *62*(2), 450–460.
40. Hartis, C. I. (2024). "Pharmacy is a profession devoted to helping patients": Investigating the ever-transforming role of pharmacists post COVID-19. *OhioLink.edu*.
41. Awais, M., Naseer, M., Khan, S., Anwer, R. M., Cholakkal, H., Shah, M., Yang, M. H., & Khan, F. S. (2025). Foundation models defining a new era in vision: A survey and outlook. *IEEE Transactions on Pattern Analysis and Machine Intelligence*.
42. Sun, J., Zheng, C., Xie, E., Liu, Z., Chu, R., Qiu, J., Xu, J., Ding, M., Li, H., Geng, M., & Wu, Y. (2025). A survey of reasoning with foundation models: Concepts, methodologies, and outlook. *ACM Computing Surveys, 57*(11), 1–??

43. Khan, W., Leem, S., See, K. B., Wong, J. K., Zhang, S., & Fang, R. (2025). A comprehensive survey of foundation models in medicine. *IEEE Reviews in Biomedical Engineering*.
44. Elhaddad, M., & Hamam, S. (2024). AI-driven clinical decision support systems: An ongoing pursuit of potential. https://www.ncbi.nlm.nih.gov
45. Banji, A. F., Adekola, A. D., & Dada, S. A. (2024). Telepharmacy models improving chronic disease management in underserved, remote communities. *International Medical Science Research Journal*.
46. Awala, E. V., & Olutimehin, D. (2024). Revolutionizing remote patient care: The role of machine learning and AI in enhancing tele-pharmacy services. *ResearchGate*.
47. Alahmari, R., Alrabghi, K., & Dighriri, M. (2022). An overview of the current state and perspectives of pharmacy robot and medication dispensing technology. https://www.ncbi.nlm.nih.gov
48. Um, I. S., Clough, A., & Tan, E. C. (2024). Dispensing error rates in pharmacy: A systematic review and meta-analysis. *Research in Social and Administrative Pharmacy, 20*(1), 1–9. https://www.sciencedirect.com
49. El Hajj, M. S., Asiri, R., Husband, A., & Todd, A. (2025). Medication errors in community pharmacies: A systematic review of the international literature. *PLoS One*.
50. Phan, P., Mitragotri, S., & Zhao, Z. (2023). Digital therapeutics in the clinic. https://www.ncbi.nlm.nih.gov
51. Shafai, G., & Aungst, T. D. (2023). Prescription digital therapeutics: A new frontier for pharmacists and the future of treatment. *Journal of the American Pharmacists Association*.
52. Hussian, T., Tripathy, S., & Dureja, H. (2025). Navigating the regulatory maze: A comparative analysis of digital therapeutics (DTx) regulations. *Journal of Science and Technology Policy Management*.
53. Lumbreras, A. G., Hurwitz, J. T., Liang, X., Schippers, S., Phillip, K., Bhattacharjee, S., Waters, H. C., & Malone, D. C. (2024). Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives. *Journal of Managed Care & Specialty Pharmacy, 30*(4), 313–325.
54. Zazzara, M. B., Palmer, K., Vetrano, D. L., Carfì, A., & Onder, G. (2021). Adverse drug reactions in older adults: A narrative review of the literature. *European Geriatric Medicine, 12*(3), 463–473.
55. Amangelsin, Y., Semenova, Y., Dadar, M., Aljofan, M., & Bjørklund, G. (2023). The impact of tetracycline pollution on the aquatic environment and removal strategies. *Antibiotics, 12*(3), 440. https://www.mdpi.com
56. Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023). Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. *Signal Transduction and Targeted Therapy, 8*(1), 262.
57. Mahmood, T., Momin, S., Ali, R., Naeem, A., & Khan, A. (2022). Technologies for removal of emerging contaminants from wastewater. In *Wastewater Treatment*. IntechOpen.
58. KOMI, L. S., Chianumba, E. C., Yeboah, A., Forkuo, D. O., & Mustapha, A. Y. (2021). Advances in community-led digital health strategies for expanding access in rural and underserved populations. *Iconic Research Engineering Journal, 5*(3), 299–317.
59. Blasioli, E., & Hassini, E. (2022). E-health technological ecosystems: Advanced solutions to support informal caregivers and vulnerable populations during the COVID-19 outbreak. *Telemedicine and e-Health*.
60. Batool, A., & Lopez, A. (2023). Healthcare access and regional connectivity: Bridging the gap. *Journal of Regional Connectivity and Development, 2*(2), 260–271.
61. Schiuma, G., Schettini, E., Santarsiero, F., & Carlucci, D. (2022). The transformative leadership compass: Six competencies for digital transformation entrepreneurship. *International Journal of Entrepreneurial Behavior & Research, 28*(5), 1273–1291.
62. Padua, D. (2021). The digital transformation social mindset. In *Digital Cultural Transformation: Building Strategic Mindsets via Digital Sociology* (pp. 39–85). Springer.
63. Ahmad, T., Aakula, A., Ottori, M., & Saini, V. (2022). Developing a strategic roadmap for digital transformation. *Journal of Computational Intelligence and Robotics, 2*(2), 28–68.
64. Ibrahim, U., & Xue, M. (2024). Exploring opportunities for online pharmacy design for Moroccan citizens. *Advanced Design Research*. https://www.sciencedirect.com
65. Ezeudoka, B. C., & Fan, M. (2024). Determinants of behavioral intentions to use an e-pharmacy service: Insights from TAM theory and the moderating influence of technological literacy. *Research in Social and Administrative Pharmacy*.
66. Fan, M., & Ukaegbu, O. C. (2024). Information literacy and intention to adopt e-pharmacy: A study based on trust and the theory of reasoned action. *BMC Health Services Research*. https://www.springer.com
67. Bates, W., Cheng, H. Y., Cheung, N. T., Jew, R., Mir, F., Tamblyn, R., & Li, Y. C. (2022). Improving smart medication management: An online expert discussion. https://www.ncbi.nlm.nih.gov
68. Arbuckle, C., Tomaszewski, D., Brown, L., Schommer, J., Morisky, D., Parlett-Pelleriti, C., & Linstead, E. (2019). Exploring the relationship of digital information sources and medication adherence.

69. Sripathi, M., & Leelavati, T. (2024). The fourth industrial revolution: A paradigm shift in healthcare delivery and management. *Digital Transformation in Healthcare 5.0*.
70. Aslam, M. M., Zakari, R. Y., Tufail, A., Ali, S., Kalinaki, K., & Shafik, W. (2024). Introduction to industry's fourth revolution and its impacts on healthcare. *Digital Transformation in Healthcare 5.0: Volume 1*.
71. Ziatdinov, R., Atteraya, M. S., & Nabiyev, R. (2024). The fifth industrial revolution as a transformative step towards society 5.0. *Societies*. https://www.mdpi.com
72. Pirmohamed, M. (2023). Pharmacogenomics: Current status and future perspectives. *Nature Reviews Genetics*.
73. Taherdoost, H., & Ghofrani, A. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intelligent Pharmacy*. https://www.sciencedirect.com
74. Qahwaji, R., Ashankyty, I., Sannan, N. S., Hazzazi, M. S., Basabrain, A. A., &Mobashir, M. (2024). Pharmacogenomics: A genetic approach to drug development and therapy. *Pharmaceuticals, 17*(7), 940. https://www.mdpi.com
75. Molla, G., & Bitew, M. (2024). Revolutionizing personalized medicine: Synergy with multi-omics data generation, main hurdles, and future perspectives. *Biomedicines*. https://www.mdpi.com
76. Baines, D., Bates, I., Bader, L., Hale, C., & Schneider, P. (2018). Conceptualising production, productivity and technology in pharmacy practice: A novel framework for policy, education and research.
77. Hattingh, L. S., Emmerton, L., Ng Cheong Tin, P., & Green, C. (2015). Utilization of community pharmacy space to enhance privacy: A qualitative study. https://www.ncbi.nlm.nih.gov
78. Herrmann, S., Giesel-Gerstmeier, J., Demuth, A., & Fenske, D. (2024). We ask and listen: A group-wide retrospective survey on satisfaction with digital medication software. https://www.ncbi.nlm.nih.gov
79. MacLure, K., & Stewart, D. (2015). Self-reported digital literacy of the pharmacy workforce in North East Scotland.
80. Del Rio-Bermudez, C., Medrano, H., Yebes, L., & Poveda, J. L. (2020). Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy.
81. Harrington, S., & Burge, T. (2018). Connecting digital pharma and e-healthcare value networks through product-service design: A conceptual model.
82. Sanderson, M., Allen, P., Osipovic, D., Petsoulas, C., Boiko, O., & Lorne, C. (2023). Developing architecture of system management in the English NHS: Evidence from a qualitative study of three integrated care systems. *BMJ Open, 13*(2), e065993. https://www.bmj.com
83. Winter, A., Ammenwerth, E., Haux, R., Marschollek, M., Steiner, B., & Jahn, F. (2023). Technological perspective: Architecture, integration, and standards. In *Health Information Systems: Technological and Management Perspectives*. Springer.
84. Jaušovec, M., & Gabrovec, B. (2023). Architectural evaluation of healthcare facilities: A comprehensive review and implications for building design. *Buildings*. https://www.mdpi.com
85. Ma, D. (2024). Standardization of community-based elderly care service quality: A multi-dimensional assessment model in Southern California. *Journal of Advanced Computing Systems*.
86. Batool, I. (2025). Real-time health monitoring using 5G networks: Deep learning–based architecture for remote patient care. *JMIRx Med*. https://www.jmir.org
87. Esu, A., & Dessì, V. (2024). Recasting solidarity during the COVID-19 pandemic: A case study. *Social Movement Studies*.
88. Gostin, L. (2023). An unparalleled collapse in global solidarity. *Pandemic Ethics: From COVID-19 to Disease X*.
89. Aginam, O. (2024). The globalization of public health and the right to solidarity. In *Research Handbook on International Solidarity and the Law*. Edward Elgar Publishing.
90. Muqsith, M. A. (n.d.). Social solidarity movement to prevent the spread of COVID-19 pandemic in Indonesia. *Masyarakat*.
91. Novovic, G. (2022). Can Agenda 2030 bring about "localization"? Policy limitations of Agenda 2030 in the broader global governance system. *Development Policy Review*.
92. Maskrey, A., Jain, G., & Lavell, A. (2023). The social construction of systemic risk: Towards an actionable framework for risk governance. *Disaster Prevention and Management: An International Journal, 32*(1), 4–26.
93. Zhang, F., Lv, Y., & Sarker, M. N. I. (2024). Resilience and recovery: A systematic review of tourism governance strategies in disaster-affected regions. *International Journal of Disaster Risk Reduction, 103*, 104350.